BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32816326)

  • 1. Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma.
    Della Starza I; De Novi LA; Cavalli M; Novelli N; Soscia R; Genuardi E; Mantoan B; Drandi D; Ferrante M; Monitillo L; Barbero D; Ciabatti E; Grassi S; Bomben R; Degan M; Gattei V; Galimberti S; Di Rocco A; Martelli M; Cortelazzo S; Guarini A; Foà R; Ladetto M; Ferrero S; Del Giudice I;
    Hematol Oncol; 2020 Dec; 38(5):698-704. PubMed ID: 32816326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR.
    van der Velden VH; Willemse MJ; van der Schoot CE; Hählen K; van Wering ER; van Dongen JJ
    Leukemia; 2002 May; 16(5):928-36. PubMed ID: 11986956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
    Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
    Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin and T cell receptor gene rearrangement patterns in acute lymphoblastic leukemia are less mature in adults than in children: implications for selection of PCR targets for detection of minimal residual disease.
    Szczepański T; Langerak AW; Wolvers-Tettero IL; Ossenkoppele GJ; Verhoef G; Stul M; Petersen EJ; de Bruijn MA; van't Veer MB; van Dongen JJ
    Leukemia; 1998 Jul; 12(7):1081-8. PubMed ID: 9665194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma.
    Puig N; Sarasquete ME; Alcoceba M; Balanzategui A; Chillón MC; Sebastián E; Díaz MG; San Miguel JF; García-Sanz R
    Eur J Haematol; 2012 Oct; 89(4):328-35. PubMed ID: 22805350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias: a new molecular target for detection of minimal residual disease.
    Beishuizen A; de Bruijn MA; Pongers-Willemse MJ; Verhoeven MA; van Wering ER; Hählen K; Breit TM; de Bruin-Versteeg S; Hooijkaas H; van Dongen JJ
    Leukemia; 1997 Dec; 11(12):2200-7. PubMed ID: 9447841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
    Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
    Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders.
    Drandi D; Ferrero S; Ladetto M
    Methods Mol Biol; 2018; 1768():229-256. PubMed ID: 29717447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial.
    Genuardi E; Romano G; Beccuti M; Alessandria B; Mannina D; Califano C; Rota Scalabrini D; Cortelazzo S; Ladetto M; Ferrero S; Calogero RA; Cordero F
    Br J Haematol; 2021 Jul; 194(2):378-381. PubMed ID: 34002365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiplex PCR reaction for the detection and identification of immunoglobulin kappa deleting element rearrangements in B-lineage leukaemias.
    Stolz F; Panzer S; Panzer-Grümayer ER
    Br J Haematol; 1999 Aug; 106(2):486-90. PubMed ID: 10460610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
    Pongers-Willemse MJ; Verhagen OJ; Tibbe GJ; Wijkhuijs AJ; de Haas V; Roovers E; van der Schoot CE; van Dongen JJ
    Leukemia; 1998 Dec; 12(12):2006-14. PubMed ID: 9844931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang.
    Gimenez E; Chauvet M; Rabin L; Puteaud I; Duley S; Hamaidia S; Bruder J; Rolland-Neyret V; Le Gouill S; Tournilhac O; Voog E; Maisonneuve H; Jacob MC; Leroux D; Béné MC; Formisano-Tréziny C; Gabert J; Gressin R; Callanan MB
    Br J Haematol; 2012 Jul; 158(2):186-197. PubMed ID: 22626453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related patterns of immunoglobulin and T-cell receptor gene rearrangements in precursor-B-ALL: implications for detection of minimal residual disease.
    van der Velden VH; Szczepanski T; Wijkhuijs JM; Hart PG; Hoogeveen PG; Hop WC; van Wering ER; van Dongen JJ
    Leukemia; 2003 Sep; 17(9):1834-44. PubMed ID: 12970784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.
    Della Starza I; Cavalli M; De Novi LA; Genuardi E; Mantoan B; Drandi D; Barbero D; Ciabatti E; Grassi S; Gazzola A; Mannu C; Agostinelli C; Piccaluga PP; Bomben R; Degan M; Gattei V; Guarini A; Foà R; Galimberti S; Ladetto M; Ferrero S; Del Giudice I;
    Hematol Oncol; 2019 Oct; 37(4):368-374. PubMed ID: 31325190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.
    Ladetto M; Brüggemann M; Monitillo L; Ferrero S; Pepin F; Drandi D; Barbero D; Palumbo A; Passera R; Boccadoro M; Ritgen M; Gökbuget N; Zheng J; Carlton V; Trautmann H; Faham M; Pott C
    Leukemia; 2014 Jun; 28(6):1299-307. PubMed ID: 24342950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease detection in Tunisian B-acute lymphoblastic leukemia based on immunoglobulin gene rearrangements.
    Besbes S; Hamadou WS; Boulland ML; Youssef YB; Achour B; Regaieg H; Khelif A; Fest T; Soua Z
    Braz J Med Biol Res; 2017 Jan; 50(1):e5426. PubMed ID: 28099581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGH and IGK gene rearrangements as PCR targets for pediatric Burkitt's lymphoma and mature B-ALL MRD analysis.
    Lovisa F; Mussolin L; Corral L; Pillon M; Cazzaniga G; Biondi A; Rosolen A
    Lab Invest; 2009 Oct; 89(10):1182-6. PubMed ID: 19668242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.
    Pongers-Willemse MJ; Seriu T; Stolz F; d'Aniello E; Gameiro P; Pisa P; Gonzalez M; Bartram CR; Panzer-Grümayer ER; Biondi A; San Miguel JF; van Dongen JJ
    Leukemia; 1999 Jan; 13(1):110-8. PubMed ID: 10049045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined IKZF1 and IG markers as new tools for diagnosis and minimal residual disease assessment in Tunisian B-ALL.
    Besbes S; Hamadou WS; Boulland ML; Lefranc MP; Ben Youssef Y; Achour B; Khelif A; Fest T; Soua Z
    Bull Cancer; 2016 Oct; 103(10):822-828. PubMed ID: 27614734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Identification of immunoglobulin and T-cell receptor gene rearrangements--prerequisite for monitoring of minimal residual disease in Polish acute lymphoblastic leukemia patients based on European standards. Preliminary results].
    Dawidowska M; Derwich K; Szczepański T; Jółkowska J; Witt M; Wachowiak J
    Med Wieku Rozwoj; 2006; 10(1 Pt 2):323-34. PubMed ID: 17028396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.